Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lixudebart in Advanced Liver Fibrosis and Mild Cirrhosis
NCT05939947Phase 1Completed
- Sponsor
- Alentis Therapeutics
- Start
- Apr 2023
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial in Liver Fibrosis (LF) and Liver cirrhosis (LC) comparing ALE.F02 with Placebo (2 arms). Primary endpoint: Pharmacokinetics profile of ALE.F02. Started Apr 2023; status: completed.
02
Drugs
lixudebart
03
Conditions
Liver Fibrosis (LF)Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT05939947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05939947.